This site is intended for health professionals only
Thursday 27 June 2019
Share |

Topic: multiple sclerosis

January 12, 2018
If licensed, ocrelizumab will be the first and only treatment option for adults in the European Union with primary progressive multiple sclerosis

Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of ocrelizumab for adults with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for adults with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

 

November 10, 2017
If licensed, ocrelizumab will be an important new treatment option for adults with active relapsing forms of multiple sclerosis, approved on the basis of superior efficacy on three major markers of disease activity and disability progression compared to comparative control groups

Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of ocrelizumab for adults with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for adults with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

 

October 5, 2017
Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone® 40mg.

Synthon has announced that it has successfully concluded the decentralised procedures for glatiramer acetate 40mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe.

 

Synthon received regulatory clearance in all 27 EU/EEA member states involved in the procedures. Granting of national marketing authorizations will follow in the near future.
 

July 13, 2017
Report finds three quarters of UK MS specialists surveyed agree one in four people with MS surveyed were not even aware that treatments could help delay the onset of disability

Sanofi and its specialty care global business unit, Sanofi Genzyme, has published a report - The Missing Pieces, showing that the majority (74%) of UK multiple sclerosis (MS) healthcare professionals who completed a survey believe that people with MS face delays in starting on disease modifying treatments (DMTs).1

 

May 22, 2017
In support of World MS Day’s official #LifewithMS theme, Teva launches social media campaign to raise awareness of challenges people can face in managing MS through key life moments

Teva Pharmaceuticals Europe has announced the launch of its ‘Life Moments with MS’ campaign – a disease awareness initiative, highlighting the challenges faced by MS patients in managing their condition through changing life circumstances – such as moving out, changing jobs or starting a family.

 

In the run up to World MS Day on 31 May, Teva will be distributing multimedia content and resources across its social media channels to promote awareness and encourage dialogue amongst MS patients and their physicians.

September 19, 2016
Real world findings presented at ECTRIMS demonstrate that Biogen's Tecfidera reduced the risk of first relapse versus competitors

Data, from both real-world and clinical settings, presented at ECTRIMS, demonstrate that dimethyl fumarate delivers consistent1 and sustained efficacy2 among patients with relapsing-remitting multiple sclerosis (RRMS), and adds to its well-characterised safety profile for up to nine years of treatment.3

 

March 10, 2015
The treatment, which was developed to treat cancers such as leukaemia and lymphoma and is being used at the Royal Hallamshire Hospital, Sheffield, is the first to significantly reverse disability of MS in certain patients.

The treatment, which was developed to treat cancers such as leukaemia and lymphoma and is being used at the Royal Hallamshire Hospital, Sheffield, is the first to significantly reverse disability of MS in certain patients.
 

October 10, 2014
Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity.

Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity. (1)
 

August 18, 2014
The All Wales Medicines Strategy Group is the first national assessment body to recommend Sativex Oromucosal Spray for use within NHS Wales for the treatment of spasticity associated with multiple sclerosis.

 

October 29, 2010
State-of-the-art technology at a new

teaser

October 15, 2010
Trials of a potential new drug to treat multiple sclerosis have proved successful after it was shown to significantly cut relapses in patients who took a once-daily oral treatment

teaser

September 23, 2010
An experiment should be carried out in Scotland to see if the fight to combat multiple sclerosis (MS) could be helped with vitamin D supplements

teaser

September 22, 2010
Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this disease

teaser

September 10, 2010
New official approval of Questcor Pharmaceuticals' Acthar gel, which treats infantile spasms in multiple sclerosis patients, will take more time because of delays over the wording of the label and medication guide

teaser

September 10, 2010
Russia is first country to approve Gilenya for the treatment of relapsing remitting MS, the most common form of the disease

teaser

April 13, 2010
Data presented at the American Academy of Neurology show annual relapse rates reduced by 62% in newly treated patients

teaser

October 7, 2009
Trials of multiple sclerosis (MS) treatment glatiramer acetate show that it can significantly delay the full onset of the disease

teaser

September 30, 2009
Two-year phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression

teaser

August 18, 2009
A simple drug used to lower blood pressure could be the key to fighting multiple sclerosis

teaser

August 17, 2009
Extavia is the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease

teaser

July 1, 2009
Preliminary interim efficacy analysis showed no clinically relevant benefit for patients

teaser

April 29, 2009
Data shows 80-83% of MS patients on oral FTY720 were relapse-free for one year

teaser

April 20, 2009
People suffering from MS and cancer offered new hope after scientists identify genetic "brakes" which could slow or stop the diseases

teaser

April 2, 2009
Genzyme assumes primary responsibility for the development and commercialisation of Alemtuzumab for multiple sclerosis

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine